Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
SKU ID : QYR-21641846 | Publishing Date : 09-Sep-2022 | No. of pages : 120
Detailed TOC of Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
1 Report Overview1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Anticholinesterases
1.2.3 Immunosuppressants
1.2.4 Intravenous Immune Globulins
1.3 Market Segment by Application
1.3.1 Global Myasthenia Gravis Drugs Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Myasthenia Gravis Drugs Market Size (2017-2028)
2.1.1 Global Myasthenia Gravis Drugs Revenue (2017-2028)
2.1.2 Global Myasthenia Gravis Drugs Sales (2017-2028)
2.2 Global Myasthenia Gravis Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Myasthenia Gravis Drugs Sales by Regions (2017-2022)
2.2.2 Global Myasthenia Gravis Drugs Revenue by Regions (2017-2022)
2.3 Global Myasthenia Gravis Drugs Market Size Forecast by Region
2.3.1 Global Myasthenia Gravis Drugs Sales Forecast by Region (2023-2028)
2.3.2 Global Myasthenia Gravis Drugs Revenue Forecast by Region (2023-2028)
2.4 Global Top Myasthenia Gravis Drugs Regions (Countries) Ranking by Market Size
2.5 Myasthenia Gravis Drugs Market Dynamics
2.5.1 Myasthenia Gravis Drugs Market Trends
2.5.2 Myasthenia Gravis Drugs Market Drivers
2.5.3 Myasthenia Gravis Drugs Market Challenges
2.5.4 Myasthenia Gravis Drugs Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Myasthenia Gravis Drugs Manufacturers by Sales (2017-2022)
3.1.1 Global Myasthenia Gravis Drugs Sales by Manufacturers (2017-2022)
3.1.2 Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Myasthenia Gravis Drugs Sales in 2021
3.2 Global Top Manufacturers Myasthenia Gravis Drugs by Revenue
3.2.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Top Myasthenia Gravis Drugs Manufacturers Covered: Ranking by Revenue
3.2.3 Global Myasthenia Gravis Drugs Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2021)
3.4 Global Myasthenia Gravis Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
3.7 Key Manufacturers Myasthenia Gravis Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Myasthenia Gravis Drugs Market Size by Type
4.1 Global Myasthenia Gravis Drugs Historic Market Review by Type (2017-2022)
4.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Type (2017-2022)
4.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2022)
4.1.3 Myasthenia Gravis Drugs Price by Type (2017-2022)
4.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2023-2028)
4.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type (2023-2028)
4.2.3 Myasthenia Gravis Drugs Price Forecast by Type (2023-2028)
5 Global Myasthenia Gravis Drugs Market Size by Application
5.1 Global Myasthenia Gravis Drugs Historic Market Review by Application (2017-2022)
5.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Application (2017-2022)
5.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2022)
5.1.3 Myasthenia Gravis Drugs Price by Application (2017-2022)
5.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2023-2028)
5.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application (2023-2028)
5.2.3 Myasthenia Gravis Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Myasthenia Gravis Drugs Sales Breakdown by Company
6.1.1 North America Myasthenia Gravis Drugs Sales by Company (2017-2022)
6.1.2 North America Myasthenia Gravis Drugs Revenue by Company (2017-2022)
6.2 North America Myasthenia Gravis Drugs Market Size by Type
6.2.1 North America Myasthenia Gravis Drugs Sales by Type (2017-2028)
6.2.2 North America Myasthenia Gravis Drugs Revenue by Type (2017-2028)
6.3 North America Myasthenia Gravis Drugs Market Size by Application
6.3.1 North America Myasthenia Gravis Drugs Sales by Application (2017-2028)
6.3.2 North America Myasthenia Gravis Drugs Revenue by Application (2017-2028)
6.4 North America Myasthenia Gravis Drugs Market Size by Country
6.4.1 North America Myasthenia Gravis Drugs Sales by Country (2017-2028)
6.4.2 North America Myasthenia Gravis Drugs Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Myasthenia Gravis Drugs Sales Breakdown by Company
7.1.1 Europe Myasthenia Gravis Drugs Sales by Company (2017-2022)
7.1.2 Europe Myasthenia Gravis Drugs Revenue by Company (2017-2022)
7.2 Europe Myasthenia Gravis Drugs Market Size by Type
7.2.1 Europe Myasthenia Gravis Drugs Sales by Type (2017-2028)
7.2.2 Europe Myasthenia Gravis Drugs Revenue by Type (2017-2028)
7.3 Europe Myasthenia Gravis Drugs Market Size by Application
7.3.1 Europe Myasthenia Gravis Drugs Sales by Application (2017-2028)
7.3.2 Europe Myasthenia Gravis Drugs Revenue by Application (2017-2028)
7.4 Europe Myasthenia Gravis Drugs Market Size by Country
7.4.1 Europe Myasthenia Gravis Drugs Sales by Country (2017-2028)
7.4.2 Europe Myasthenia Gravis Drugs Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Myasthenia Gravis Drugs Sales Breakdown by Company
8.1.1 Asia Pacific Myasthenia Gravis Drugs Sales by Company (2017-2022)
8.1.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Company (2017-2022)
8.2 Asia Pacific Myasthenia Gravis Drugs Market Size by Type
8.2.1 Asia Pacific Myasthenia Gravis Drugs Sales by Type (2017-2028)
8.2.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Myasthenia Gravis Drugs Market Size by Application
8.3.1 Asia Pacific Myasthenia Gravis Drugs Sales by Application (2017-2028)
8.3.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Myasthenia Gravis Drugs Market Size by Region
8.4.1 Asia Pacific Myasthenia Gravis Drugs Sales by Region
8.4.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Myasthenia Gravis Drugs Sales Breakdown by Company
9.1.1 Latin America Myasthenia Gravis Drugs Sales by Company (2017-2022)
9.1.2 Latin America Myasthenia Gravis Drugs Revenue by Company (2017-2022)
9.2 Latin America Myasthenia Gravis Drugs Market Size by Type
9.2.1 Latin America Myasthenia Gravis Drugs Sales by Type (2017-2028)
9.2.2 Latin America Myasthenia Gravis Drugs Revenue by Type (2017-2028)
9.3 Latin America Myasthenia Gravis Drugs Market Size by Application
9.3.1 Latin America Myasthenia Gravis Drugs Sales by Application (2017-2028)
9.3.2 Latin America Myasthenia Gravis Drugs Revenue by Application (2017-2028)
9.4 Latin America Myasthenia Gravis Drugs Market Size by Country
9.4.1 Latin America Myasthenia Gravis Drugs Sales by Country (2017-2028)
9.4.2 Latin America Myasthenia Gravis Drugs Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Company
10.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Company (2017-2022)
10.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Company (2017-2022)
10.2 Middle East and Africa Myasthenia Gravis Drugs Market Size by Type
10.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2017-2028)
10.2.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Myasthenia Gravis Drugs Market Size by Application
10.3.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2017-2028)
10.3.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Myasthenia Gravis Drugs Market Size by Country
10.4.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2017-2028)
10.4.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Flamel Technologies
11.1.1 Flamel Technologies Corporation Information
11.1.2 Flamel Technologies Overview
11.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Flamel Technologies Myasthenia Gravis Drugs Products and Services
11.1.5 Flamel Technologies Myasthenia Gravis Drugs SWOT Analysis
11.1.6 Flamel Technologies Recent Developments
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Corporation Information
11.2.2 F. Hoffmann-La Roche Overview
11.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products and Services
11.2.5 F. Hoffmann-La Roche Myasthenia Gravis Drugs SWOT Analysis
11.2.6 F. Hoffmann-La Roche Recent Developments
11.3 Grifols
11.3.1 Grifols Corporation Information
11.3.2 Grifols Overview
11.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Grifols Myasthenia Gravis Drugs Products and Services
11.3.5 Grifols Myasthenia Gravis Drugs SWOT Analysis
11.3.6 Grifols Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Pfizer Myasthenia Gravis Drugs Products and Services
11.4.5 Pfizer Myasthenia Gravis Drugs SWOT Analysis
11.4.6 Pfizer Recent Developments
11.5 Takeda
11.5.1 Takeda Corporation Information
11.5.2 Takeda Overview
11.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Takeda Myasthenia Gravis Drugs Products and Services
11.5.5 Takeda Myasthenia Gravis Drugs SWOT Analysis
11.5.6 Takeda Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Overview
11.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Novartis Myasthenia Gravis Drugs Products and Services
11.6.5 Novartis Myasthenia Gravis Drugs SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 Bausch Health
11.7.1 Bausch Health Corporation Information
11.7.2 Bausch Health Overview
11.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Bausch Health Myasthenia Gravis Drugs Products and Services
11.7.5 Bausch Health Myasthenia Gravis Drugs SWOT Analysis
11.7.6 Bausch Health Recent Developments
11.8 Alexion Pharmaceuticals
11.8.1 Alexion Pharmaceuticals Corporation Information
11.8.2 Alexion Pharmaceuticals Overview
11.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products and Services
11.8.5 Alexion Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis
11.8.6 Alexion Pharmaceuticals Recent Developments
11.9 Catalyst Pharmaceuticals
11.9.1 Catalyst Pharmaceuticals Corporation Information
11.9.2 Catalyst Pharmaceuticals Overview
11.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products and Services
11.9.5 Catalyst Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis
11.9.6 Catalyst Pharmaceuticals Recent Developments
11.10 CSL
11.10.1 CSL Corporation Information
11.10.2 CSL Overview
11.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 CSL Myasthenia Gravis Drugs Products and Services
11.10.5 CSL Myasthenia Gravis Drugs SWOT Analysis
11.10.6 CSL Recent Developments
11.11 Curavac
11.11.1 Curavac Corporation Information
11.11.2 Curavac Overview
11.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Curavac Myasthenia Gravis Drugs Products and Services
11.11.5 Curavac Recent Developments
11.12 Cytokinetics
11.12.1 Cytokinetics Corporation Information
11.12.2 Cytokinetics Overview
11.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Cytokinetics Myasthenia Gravis Drugs Products and Services
11.12.5 Cytokinetics Recent Developments
11.13 Galencia
11.13.1 Galencia Corporation Information
11.13.2 Galencia Overview
11.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 Galencia Myasthenia Gravis Drugs Products and Services
11.13.5 Galencia Recent Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Corporation Information
11.14.2 GlaxoSmithKline Overview
11.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Products and Services
11.14.5 GlaxoSmithKline Recent Developments
11.15 Lupin Pharmaceuticals
11.15.1 Lupin Pharmaceuticals Corporation Information
11.15.2 Lupin Pharmaceuticals Overview
11.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Products and Services
11.15.5 Lupin Pharmaceuticals Recent Developments
11.16 Mitsubishi Tanabe Pharma
11.16.1 Mitsubishi Tanabe Pharma Corporation Information
11.16.2 Mitsubishi Tanabe Pharma Overview
11.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Products and Services
11.16.5 Mitsubishi Tanabe Pharma Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Myasthenia Gravis Drugs Value Chain Analysis
12.2 Myasthenia Gravis Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myasthenia Gravis Drugs Production Mode & Process
12.4 Myasthenia Gravis Drugs Sales and Marketing
12.4.1 Myasthenia Gravis Drugs Sales Channels
12.4.2 Myasthenia Gravis Drugs Distributors
12.5 Myasthenia Gravis Drugs Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Figures, Tables and Charts Available in Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
List of TablesTable 1. Global Myasthenia Gravis Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Anticholinesterases
Table 3. Major Manufacturers of Immunosuppressants
Table 4. Major Manufacturers of Intravenous Immune Globulins
Table 5. Global Myasthenia Gravis Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Myasthenia Gravis Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 7. Global Myasthenia Gravis Drugs Sales by Region (2017-2022) & (MT)
Table 8. Global Myasthenia Gravis Drugs Sales Market Share by Region (2017-2022)
Table 9. Global Myasthenia Gravis Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2017-2022)
Table 11. Global Myasthenia Gravis Drugs Sales Forecast by Region (2023-2028) & (MT)
Table 12. Global Myasthenia Gravis Drugs Sales Market Share Forecast by Region (2023-2028)
Table 13. Global Myasthenia Gravis Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 15. Top Myasthenia Gravis Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 16. Myasthenia Gravis Drugs Market Trends
Table 17. Myasthenia Gravis Drugs Market Drivers
Table 18. Myasthenia Gravis Drugs Market Challenges
Table 19. Myasthenia Gravis Drugs Market Restraints
Table 20. Global Myasthenia Gravis Drugs Sales by Manufacturers (2017-2022) & (MT)
Table 21. Global Myasthenia Gravis Drugs Sales Share by Manufacturers (2017-2022)
Table 22. Global Myasthenia Gravis Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Ranking of Global Top Myasthenia Gravis Drugs Manufacturers by Revenue (US$ Million) in 2021
Table 24. Myasthenia Gravis Drugs Revenue Share by Manufacturers (2017-2022)
Table 25. Global Myasthenia Gravis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2021)
Table 27. Key Manufacturers Myasthenia Gravis Drugs Average Selling Price (ASP) & (2017-2022) & (USD/Kg)
Table 28. Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution
Table 29. Key Manufacturers Myasthenia Gravis Drugs Area Served
Table 30. Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
Table 31. Key Manufacturers Myasthenia Gravis Drugs Product Type
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Myasthenia Gravis Drugs Sales (MT) by Type (2017-2022)
Table 34. Global Myasthenia Gravis Drugs Sales Share by Type (2017-2022)
Table 35. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2017-2022)
Table 36. Global Myasthenia Gravis Drugs Price (MT) by Type (2017-2022)
Table 37. Global Myasthenia Gravis Drugs Sales (MT) by Type (2023-2028)
Table 38. Global Myasthenia Gravis Drugs Sales Share by Type (2023-2028)
Table 39. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2023-2028)
Table 40. Global Myasthenia Gravis Drugs Revenue Share by Type (2023-2028)
Table 41. Global Myasthenia Gravis Drugs Price (MT) by Type (2023-2028)
Table 42. Global Myasthenia Gravis Drugs Sales (MT) by Application (2017-2022)
Table 43. Global Myasthenia Gravis Drugs Sales Share by Application (2017-2022)
Table 44. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2017-2022)
Table 45. Global Myasthenia Gravis Drugs Price (MT) by Application (2017-2022)
Table 46. Global Myasthenia Gravis Drugs Sales (MT) by Application (2023-2028)
Table 47. Global Myasthenia Gravis Drugs Sales Share by Application (2023-2028)
Table 48. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2023-2028)
Table 49. Global Myasthenia Gravis Drugs Revenue Share by Application (2023-2028)
Table 50. Global Myasthenia Gravis Drugs Price (MT) by Application (2023-2028)
Table 51. North America Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT)
Table 52. North America Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022)
Table 53. North America Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 54. North America Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022)
Table 55. North America Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT)
Table 56. North America Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT)
Table 57. North America Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 58. North America Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 59. North America Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT)
Table 60. North America Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT)
Table 61. North America Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 62. North America Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 63. North America Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT)
Table 64. North America Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT)
Table 65. North America Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 66. North America Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 67. Europe Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT)
Table 68. Europe Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022)
Table 69. Europe Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 70. Europe Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022)
Table 71. Europe Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT)
Table 72. Europe Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT)
Table 73. Europe Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 74. Europe Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 75. Europe Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT)
Table 76. Europe Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT)
Table 77. Europe Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 78. Europe Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 79. Europe Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT)
Table 80. Europe Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT)
Table 81. Europe Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 82. Europe Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 83. Asia Pacific Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT)
Table 84. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022)
Table 85. Asia Pacific Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 86. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022)
Table 87. Asia Pacific Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT)
Table 88. Asia Pacific Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT)
Table 89. Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 90. Asia Pacific Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 91. Asia Pacific Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT)
Table 92. Asia Pacific Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT)
Table 93. Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 94. Asia Pacific Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 95. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2017-2022) & (MT)
Table 96. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2023-2028) & (MT)
Table 97. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 98. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 99. Latin America Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT)
Table 100. Latin America Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022)
Table 101. Latin America Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 102. Latin America Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022)
Table 103. Latin America Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT)
Table 104. Latin America Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT)
Table 105. Latin America Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 106. Latin America Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 107. Latin America Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT)
Table 108. Latin America Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT)
Table 109. Latin America Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 110. Latin America Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 111. Latin America Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT)
Table 112. Latin America Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT)
Table 113. Latin America Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 114. Latin America Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Myasthenia Gravis Drugs Sales by Company (2017-2022) & (MT)
Table 116. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Company (2017-2022)
Table 117. Middle East and Africa Myasthenia Gravis Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 118. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Company (2017-2022)
Table 119. Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2017-2022) & (MT)
Table 120. Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2023-2028) & (MT)
Table 121. Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 122. Middle East and Africa Myasthenia Gravis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 123. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2017-2022) & (MT)
Table 124. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2023-2028) & (MT)
Table 125. Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 126. Middle East and Africa Myasthenia Gravis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 127. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2017-2022) & (MT)
Table 128. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2023-2028) & (MT)
Table 129. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 130. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 131. Flamel Technologies Corporation Information
Table 132. Flamel Technologies Description and Overview
Table 133. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 134. Flamel Technologies Myasthenia Gravis Drugs Product and Services
Table 135. Flamel Technologies Myasthenia Gravis Drugs SWOT Analysis
Table 136. Flamel Technologies Recent Developments
Table 137. F. Hoffmann-La Roche Corporation Information
Table 138. F. Hoffmann-La Roche Description and Overview
Table 139. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 140. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product and Services
Table 141. F. Hoffmann-La Roche Myasthenia Gravis Drugs SWOT Analysis
Table 142. F. Hoffmann-La Roche Recent Developments
Table 143. Grifols Corporation Information
Table 144. Grifols Description and Overview
Table 145. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 146. Grifols Myasthenia Gravis Drugs Product and Services
Table 147. Grifols Myasthenia Gravis Drugs SWOT Analysis
Table 148. Grifols Recent Developments
Table 149. Pfizer Corporation Information
Table 150. Pfizer Description and Overview
Table 151. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 152. Pfizer Myasthenia Gravis Drugs Product and Services
Table 153. Pfizer Myasthenia Gravis Drugs SWOT Analysis
Table 154. Pfizer Recent Developments
Table 155. Takeda Corporation Information
Table 156. Takeda Description and Overview
Table 157. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 158. Takeda Myasthenia Gravis Drugs Product and Services
Table 159. Takeda Myasthenia Gravis Drugs SWOT Analysis
Table 160. Takeda Recent Developments
Table 161. Novartis Corporation Information
Table 162. Novartis Description and Overview
Table 163. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 164. Novartis Myasthenia Gravis Drugs Product and Services
Table 165. Novartis Myasthenia Gravis Drugs SWOT Analysis
Table 166. Novartis Recent Developments
Table 167. Bausch Health Corporation Information
Table 168. Bausch Health Description and Overview
Table 169. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 170. Bausch Health Myasthenia Gravis Drugs Product and Services
Table 171. Bausch Health Myasthenia Gravis Drugs SWOT Analysis
Table 172. Bausch Health Recent Developments
Table 173. Alexion Pharmaceuticals Corporation Information
Table 174. Alexion Pharmaceuticals Description and Overview
Table 175. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 176. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product and Services
Table 177. Alexion Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis
Table 178. Alexion Pharmaceuticals Recent Developments
Table 179. Catalyst Pharmaceuticals Corporation Information
Table 180. Catalyst Pharmaceuticals Description and Overview
Table 181. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 182. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product and Services
Table 183. Catalyst Pharmaceuticals Myasthenia Gravis Drugs SWOT Analysis
Table 184. Catalyst Pharmaceuticals Recent Developments
Table 185. CSL Corporation Information
Table 186. CSL Description and Overview
Table 187. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 188. CSL Myasthenia Gravis Drugs Product and Services
Table 189. CSL Myasthenia Gravis Drugs SWOT Analysis
Table 190. CSL Recent Developments
Table 191. Curavac Corporation Information
Table 192. Curavac Description and Overview
Table 193. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 194. Curavac Myasthenia Gravis Drugs Product and Services
Table 195. Curavac Recent Developments
Table 196. Cytokinetics Corporation Information
Table 197. Cytokinetics Description and Overview
Table 198. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 199. Cytokinetics Myasthenia Gravis Drugs Product and Services
Table 200. Cytokinetics Recent Developments
Table 201. Galencia Corporation Information
Table 202. Galencia Description and Overview
Table 203. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 204. Galencia Myasthenia Gravis Drugs Product and Services
Table 205. Galencia Recent Developments
Table 206. GlaxoSmithKline Corporation Information
Table 207. GlaxoSmithKline Description and Overview
Table 208. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 209. GlaxoSmithKline Myasthenia Gravis Drugs Product and Services
Table 210. GlaxoSmithKline Recent Developments
Table 211. Lupin Pharmaceuticals Corporation Information
Table 212. Lupin Pharmaceuticals Description and Overview
Table 213. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 214. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product and Services
Table 215. Lupin Pharmaceuticals Recent Developments
Table 216. Mitsubishi Tanabe Pharma Corporation Information
Table 217. Mitsubishi Tanabe Pharma Description and Overview
Table 218. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2017-2022)
Table 219. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product and Services
Table 220. Mitsubishi Tanabe Pharma Recent Developments
Table 221. Key Raw Materials Lists
Table 222. Raw Materials Key Suppliers Lists
Table 223. Myasthenia Gravis Drugs Distributors List
Table 224. Myasthenia Gravis Drugs Customers List
Table 225. Research Programs/Design for This Report
Table 226. Key Data Information from Secondary Sources
Table 227. Key Data Information from Primary Sources
List of Figures
Figure 1. Myasthenia Gravis Drugs Product Picture
Figure 2. Global Myasthenia Gravis Drugs Sales Market Share by Type in 2021 & 2028
Figure 3. Anticholinesterases Product Picture
Figure 4. Immunosuppressants Product Picture
Figure 5. Intravenous Immune Globulins Product Picture
Figure 6. Global Myasthenia Gravis Drugs Sales Market Share by Application in 2021 & 2028
Figure 7. Hospitals Use Case
Figure 8. Clinics Use Case
Figure 9. Myasthenia Gravis Drugs Report Years Considered
Figure 10. Global Myasthenia Gravis Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Myasthenia Gravis Drugs Market Size 2017-2028 (US$ Million)
Figure 12. Global Myasthenia Gravis Drugs Sales (2017-2022) & (MT)
Figure 13. Global Myasthenia Gravis Drugs Market Size Market Share by Region: 2021 VS 2028
Figure 14. Global Myasthenia Gravis Drugs Sales Market Share by Region (2017-2022)
Figure 15. Global Myasthenia Gravis Drugs Sales Market Share by Region in 2021
Figure 16. Global Myasthenia Gravis Drugs Revenue Market Share by Region in 2017 VS 2021
Figure 17. Global Myasthenia Gravis Drugs Sales Share by Manufacturers in 2021
Figure 18. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Drugs Sales in 2021
Figure 19. Myasthenia Gravis Drugs Revenue Share by Manufacturers in 2021
Figure 20. Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 21. Global Myasthenia Gravis Drugs Revenue Share by Type (2017-2022)
Figure 22. Global Myasthenia Gravis Drugs Revenue Growth Rate by Type in 2017 & 2021
Figure 23. Global Myasthenia Gravis Drugs Revenue Share by Application (2017-2022)
Figure 24. Global Myasthenia Gravis Drugs Revenue Growth Rate by Application in 2017 & 2021
Figure 25. North America Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028)
Figure 26. North America Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028)
Figure 27. North America Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028)
Figure 28. North America Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028)
Figure 29. North America Myasthenia Gravis Drugs Sales Share by Country (2017-2028)
Figure 30. North America Myasthenia Gravis Drugs Revenue Share by Country (2017-2028)
Figure 31. U.S. Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 32. Canada Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 33. Europe Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028)
Figure 34. Europe Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028)
Figure 35. Europe Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028)
Figure 36. Europe Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Europe Myasthenia Gravis Drugs Sales Share by Country (2017-2028)
Figure 38. Europe Myasthenia Gravis Drugs Revenue Share by Country (2017-2028)
Figure 39. Germany Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 40. France Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 41. U.K. Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Italy Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. Russia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 44. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028)
Figure 45. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028)
Figure 46. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028)
Figure 47. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028)
Figure 48. Asia Pacific Myasthenia Gravis Drugs Sales Share by Region (2017-2028)
Figure 49. Asia Pacific Myasthenia Gravis Drugs Revenue Share by Region (2017-2028)
Figure 50. China Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Japan Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. South Korea Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 53. India Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 54. Australia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 55. Taiwan Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 56. Indonesia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 57. Thailand Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Malaysia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 59. Philippines Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 60. Vietnam Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Latin America Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028)
Figure 62. Latin America Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028)
Figure 63. Latin America Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028)
Figure 64. Latin America Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028)
Figure 65. Latin America Myasthenia Gravis Drugs Sales Share by Country (2017-2028)
Figure 66. Latin America Myasthenia Gravis Drugs Revenue Share by Country (2017-2028)
Figure 67. Mexico Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Brazil Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 69. Argentina Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 70. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Type (2017-2028)
Figure 72. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Myasthenia Gravis Drugs Sales Share by Country (2017-2028)
Figure 75. Middle East and Africa Myasthenia Gravis Drugs Revenue Share by Country (2017-2028)
Figure 76. Turkey Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 77. Saudi Arabia Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 78. U.A.E Myasthenia Gravis Drugs Revenue (2017-2028) & (US$ Million)
Figure 79. Myasthenia Gravis Drugs Value Chain
Figure 80. Myasthenia Gravis Drugs Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed
Keyplayers in Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Flamel TechnologiesF. Hoffmann-La Roche
Grifols
Pfizer
Takeda
Novartis
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
24/7 Research Support
Phone: +1 424 253 0807 
